Skip to main content
Premium Trial:

Request an Annual Quote

ABI, BG Medicine Team on Industrial-Scale Biomarker Research

NEW YORK (GenomeWeb News) - Applied Biosystems and BG Medicine are partnering on a research project that will use ABI technology to develop methods for enhancing the scale of biomarker development, ABI said today.
 
Under the terms of the two-year agreement, BG medicine will integrate ABI technology within its proteomic and metabolomic research pipeline, which BG terms “systems pharmacology.”  
 
BG Medicine focuses on the molecular characterization of disease states and drug response and is already using ABI's mass spectrometers, software, and reagents "in an industrial setting,"
ABI said. Under the current agreement, BG plans to use the same tools to expand the scale of ABI's biomarker discovery and proteomics and metabolomics technologies.
 
Making these advances "more relevant and applicable on a wider scale," said Laura Lauman, president of ABI's proteomics and small molecule division, "can help transform the process of drug discovery and development.
 
Financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.